Effect of Anti-Psychotic Drugs on Lipid and Prolactin Level among Sudanese patients
Keywords:
Anti-Psychotic drugs, Lipids, Prolactin, Sudanese.Abstract
A psychiatric medication is a licensed psychoactive drug taken to exert an effect on the chemical makeup of the brain and nervous system. Thus, these medications are used to treat mental disorders. The aim of the current study was to determine the effect of anti-Psychotic drugs on lipid and prolactin level among Sudanese psychotic patients. This cross-sectional
References
. Brink, T.L., Psychology: A Student Friendly Approach, pp120. 2008.
. Brink, T.L., Psychology a student friendly approach. Unit, 2008. 5: p. 88.
. Campbell, M., J.L. Rapoport, and G.M. Simpson, Antipsychotics in children and adolescents. Journal of the American Academy of Child & Adolescent Psychiatry, 1999. 38(5): p. 537-545.
. Cooper, W.O., et al., New users of antipsychotic medications among children enrolled in TennCare. Archives of pediatrics & adolescent medicine, 2004. 158(8): p. 753-759.
. Meyer, J.M., Novel antipsychotics and severe hyperlipidemia. Journal of clinical psychopharmacology, 2001. 21(4): p. 369-374.
. Wirshing, D.A., et al., The effects of novel antipsychotics on glucose and lipid levels. The Journal of clinical psychiatry, 2002. 63(10): p. 856-865.
. Ghaeli, P. and R.L. Dufresne, Serum triglyceride levels in patients treated with clozapine. American journal of health-system pharmacy, 1996. 53(17): p. 2079-2081.
. Spivak, B., et al., Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clinical neuropharmacology, 1998. 21(4): p. 245-250.
. Moreno, C., et al., Metabolic effects of second‐generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar disorders. 12(2): p. 172-184.
. Wilson, P.W.F., et al., Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation, 2005. 112(20): p. 3066-3072.
. Meyer, J.M., A retrospective comparison of weight, lipid, and glucose changes between risperidone-and olanzapine-treated inpatients: metabolic outcomes after 1 year. The Journal of clinical psychiatry, 2002. 63(5): p. 425-433.
. Sartorius, N., Physical illness in people with mental disorders. World Psychiatry, 2007. 6(1): p. 3-4.
Allison, D.B., et al., Antipsychotic-induced weight gain: a comprehensive research synthesis. American journal of Psychiatry, 1999.
. Wirshing, D.A., et al., Novel antipsychotics: comparison of weight gain liabilities. The Journal of clinical psychiatry, 1999. 60(6): p. 358-363.
. Tschoner, A., et al., Metabolic side effects of antipsychotic medication. International journal of clinical practice, 2007. 61(8): p. 1356-1370.
. Balf, G., et al., Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. Primary care companion to the Journal of clinical psychiatry, 2008. 10(1): p. 15.
. Pringsheim, T., et al., Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 20(3): p. 218-233.
. Reynolds, G.P., Z. Zhang, and X. Zhang, Polymorphism of the promoter region of the serotonin 5-HT2C receptor gene and clozapine-induced weight gain. American journal of Psychiatry, 2003.
. Osser, D.N., D.M. Najarian, and R.L. Dufresne, Olanzapine increases weight and serum triglyceride levels. Journal of Clinical Psychiatry, 1999.
. Meyer, J.M. and C.E. Koro, The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia research, 2004. 70(1): p. 1-17.
. Caro, J.J., A. Ward, and K. Robinson, The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. The Journal of clinical psychiatry, 2002. 63(12): p. 1135-1139
Downloads
Published
How to Cite
Issue
Section
License
Authors who submit papers with this journal agree to the following terms.
